Pembrolizumab Shows Further Promise for Melanoma In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected. by Brad Jones Forward Look Tackling Drug Resistance Researchers are studing new ways to keep treatments working longer. by Stephen Ornes Survivor Profile Living in the Here and Now A metastatic melanoma survivor is hopeful but realistic as new treatments become available. by Jenny Song Forward Look Cancer Immunotherapies Continue to Make Headway Drugs that harness the power of the immune system gain new approvals. by Alexandra Goho Survivor Profile Knowing Her Options When Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors. by Melissa Davlin First Person Keeping Sight of Hope A survivor keeps an eye on what's ahead after a rare cancer diagnosis. by Sue Russell Cancer Talk October 12: The Week in Cancer News A study sheds light on the difficulty patients have in accessing their medical records, and the U.S. Food and Drug Administration expands approval of the human papillomavirus vaccine. by Kate Yandell October 5: The Week in Cancer News Cancer immunology researchers are awarded a Nobel Prize, and a seventh immune checkpoint inhibitor is approved by the U.S. Food and Drug Administration. by Kate Yandell Why I Put Down My Camera A professional photographer shares advice on living in the moment after caring for his father, who had stage IV lung cancer. by Jay Perry Vaccinating Against Cancer The human papillomavirus vaccine can significantly cut recipients’ risk of several types of cancer. So why are vaccination rates relatively low in the U.S.? by Brad Jones More Posts